OTEZLA

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 7.5% last Thursday on rumors of a potential buyout and have since given up all of those gains. Alexion develops therapies for rare diseases and has been rumored to be a takeover target for Amgen, Inc. (NASDAQ: AMGN) for about a year. The...

Amgen, Inc. (NASDAQ: AMGN) is beefing up its inflammatory disease drug portfolio with a blockbuster psoriasis drug that Celgene Corporation (NASDAQ: CELG) is being forced to divest as a regulatory requirement for the completion of its previously announced merger agreement with Bristol-...

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday. There were favorable outcomes as well as disappointments. Acer Therapeutics Inc (NASDAQ: ACER) went about a freefall, shedding about 79% in a single session after the FDA issued a...

Biopharma Celgene Corporation (NASDAQ: CELG) reported first-quarter earnings, lowered its 2018 full-year EPS guidance and raised its sales guidance for the year before the open Friday.  What Happened Total net product sales of $3.53 billion in Q1 were 20 percent higher from the same...

Celgene Corporation (NASDAQ: CELG) stock tanked Thursday, dropping close to 20 percent on roughly nine times its average volume. The downside was orchestrated by weaker-than-expected third-quarter revenues announced by the company Thursday. At the time of writing, shares of Celgene were down...

Argus' David Toung downgraded shares of Celgene Corporation (NASDAQ: CELG) from Buy to Hold after fully digesting the company's first-quarter earnings report. Stay Critical, Investors According to Toung, investors have reason to be "concerned" over the company's revenue concentration from Revlimid...

Shares of Celgene Corporation (NASDAQ: CELG) were trading higher by 0.43 percent at $108.11 after the company reported its second-quarter results. Celgene said it earned $1.44 per share in the second quarter on revenue of $2.74 billion. Wall Street analysts were expecting the company to earn $1.39...

Canaccord Genuity reiterated its Buy rating and $156 price target on Celgene Corporation (NASDAQ: CELG). In the report published Friday, the analysts stated their positive outlook for the near-term data readouts for Revlimid from REMARC and Otezla in Atopic Dermatitis. Additionally, they expect...